NanoViricides, Inc. (NYSE American: NNVC) is advancing its investigational broad-spectrum antiviral drug NV-387 toward Phase II clinical trials for the treatment of measles. The company is developing a clinical trial protocol for submission to the U.S. Food and Drug Administration through an Investigational New Drug process, according to a press release. The move comes as measles cases are rising in the United States and internationally, underscoring an unmet medical need for effective treatments.
NV-387 has demonstrated antiviral activity against measles in a humanized mouse model and completed a juvenile mouse toxicity study in which no treatment-related adverse effects were observed at the highest dose tested. The drug has also completed a Phase I human safety study and is currently being evaluated in separate Phase II trials for Ebola Bundibugyo virus and mpox in the Democratic Republic of Congo. These prior results provide a foundation for the measles program and suggest the drug could be rapidly advanced if regulatory clearance is granted.
The FDA has granted NV-387 both Orphan Drug Designation and Rare Pediatric Disease Drug (RPDD) Designation for measles treatment. The RPDD designation could make NanoViricides eligible for a Priority Review Voucher following approval of a qualifying marketing application, subject to applicable requirements. A priority review voucher can be sold or transferred, potentially providing a significant financial incentive and accelerating the development of other therapies. For a clinical-stage company like NanoViricides, this represents a valuable asset that could help fund further research.
NanoViricides is a clinical-stage company creating special-purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates is based on intellectual property from TheraCour Pharma, Inc. The company’s lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, influenza, and other respiratory viral infections, as well as mpox/smallpox and measles. The company’s business model relies on licensing technology from TheraCour for specific antiviral applications. For investors, the latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC.
The full press release can be viewed at https://ibn.fm/lWeDl. This announcement is distributed by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. For more information, visit www.BioMedWire.com.
NV-387 remains investigational and has not been approved for treating measles or any other viral disease. As with any drug development effort, there can be no assurance that the drug will show sufficient effectiveness and safety for human clinical development. The company cannot project an exact date for filing an IND for any of its drugs because of dependence on external collaborators and consultants. Nevertheless, the advancement of NV-387 toward Phase II trials for measles represents a significant step in addressing a growing public health threat.


